TITLE

Diabetes drug pioglitazone (Actos): risk of fracture

AUTHOR(S)
Meymeh, Reza Heidarpour; Wooltorton, Eric
PUB. DATE
September 2007
SOURCE
CMAJ: Canadian Medical Association Journal;9/25/2007, Vol. 177 Issue 7, p723
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the drug pioglitazone which is used as monotherapy or combination therapy for type 2 diabetes mellitus. It states that the people who use this drug are more prone to have bone fracture. The drug is a thiazolidinedione (TZD) which activates perioxisome proliferator-activated receptors (PPAR) which shoot glucose utilization and reduce glucose production by the liver, and increase insulin sensitivity in adipose and muscle tissue. It can also contribute to the risk factors for osteoporosis in women.
ACCESSION #
26594454

 

Related Articles

  • High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control. OEI, LING; ZILLIKENS, M. CAROLA; DEHGHAN, ABBAS; BUITENDIJK, GABRIËLLE H. S.; CASTAÑO-BETANCOURT, MARTHA C.; ESTRADA, KAROL; STOLK, LISETTE; OEI, EDWIN H. G.; VAN MEURS, JOYCE B. J.; JANSSEN, JOSEPH A. M. J. L.; HOFMAN, ALBERT; VAN LEEUWEN, JOHANNES P. T. M.; WITTEMAN, JACQUELINE C. M.; POLS, HUIBERT A. P.; UITTERLINDEN, ANDRÉ G.; KLAVER, CAROLINE C. W.; FRANCO, OSCAR H.; RIVADENEIRA, FERNANDO // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1619 

    OBJECTIVE Individuals with type 2 diabetes have increased fracture risk despite higher d bone mineral density (BMD). Our aim was to examine the influence of glucose control on skeletal complications. RESEARCH DESIGN AND METHODS Data of 4,135 participants of the Rotterdam d Study, a prospective...

  • Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men. Yaturu, Subhashini; Bryant, Barbara; Jain, Sushil K. // Diabetes Care;Jun2007, Vol. 30 Issue 6, p1574 

    The article discusses a study on the effects of thiazolidinedione treatment on bone mineral density (BMD) among type 2 diabetic men. Risk factors that contribute to increased fracture in diabetics include falls, insulin use and functional disability. The study showed an increase in bone loss at...

  • DRUGS LINKED TO FRACTURE RISK.  // RN;Jul2009, Vol. 72 Issue 7, p15 

    The article reports that the use of thiazolidinediones (TSD) has been associated with an increased risk of bone fracture. Type 2 diabetic patients taking pioglitazone (Actos) or rosiglitazone (Avandia) experienced a higher risk of bone fracture than patients who did not take TZDs. Pioglitazone...

  • Defect Bone Health In Mice With The Akita Mutation In Ins2. Kray, Arlene; Baust, Jeff; Vaidya, Swaroopa; Mathews, Clayton E.; Hollinger, Jeffrey O. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA196 

    There is unequivocal clinical data underscoring problematic bone wound healing in the diabetic population. Fracture healing in patients with all forms of diabetes can take twice as long as nondiabetic patients. A profoundly compelling medical concern is that fracture occurrence is more prevalent...

  • Diabetes Drugs Increase Women's Fracture Risk.  // Good Medicine;Spring2009, Vol. 18 Issue 2, p5 

    The article focuses on a report by researchers at Wake Forest University and the University of East Anglia on the impact of diabetes drugs on the risk of bone fractures in women with type 2 diabetes. Ten studies of diabetes patients were analyzed and found that Avandia and Actos doubled the risk...

  • Quantitative ultrasound and vertebral fractures in patients with type 2 diabetes. Yamaguchi, Toru; Yamamoto, Masahiro; Kanazawa, Ippei; Yamauchi, Mika; Yano, Shozo; Tanaka, Nobuko; Nitta, Eri; Fukuma, Asako; Uno, Seiko; Sho-no, Tomoko; Sugimoto, Toshitsugu // Journal of Bone & Mineral Metabolism;Sep2011, Vol. 29 Issue 5, p626 

    Patients with type 2 diabetes (T2DM) are known to have increased risks of femoral neck and vertebral fractures, although their bone mineral density (BMD) is normal or even slightly increased compared to non-DM controls. This observation suggests that bone fragility not reflected by BMD, possibly...

  • Diabetes Drugs Tied to Fractures in Women. Hampton, Tracy // JAMA: Journal of the American Medical Association;4/18/2007, Vol. 297 Issue 15, p1645 

    The article states that the U.S. Food and Drug Administration has issued a warning about an increased risk of arm, hand, and lower leg fractures in women associated with the use of the drug pioglitazone, which is a thiazolidinedione used to treat type 2 diabetes. The increased risk of fracture...

  • Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea. Triplitt, Curtis; Glass, Leonard; Miyazaki, Yoshiniro; Wajcberg, Estela; Gastaldelli, Amalia; De Filippis, Elena; Cersosimo, Eugenio; DeFronzo, Ralph A. // Diabetes Care;Nov2006, Vol. 29 Issue 11, p2371 

    OBJECTIVE -- We sought to examine the mechanisms by which the addition of glargine insulin or rosiglitazone improves glycemic control in type 2 diabetic subjects poorly controlled on maximally effective doses of metformin plus sulfonylurea. RESEARCH DESIGN AND METHODS -- Subjects (aged 47 ±...

  • Nateglinide A new member of the meglitinide family for postprandial glucose control in type 2 diabetes. Schrand, Linda M.; Spanheimer, Robert G. // Formulary;Oct2000, Vol. 35 Issue 10, p798 

    Focuses on Nateglinide, an orally active secretagogue that lacks the sulfonylurea moiety, which is under review by the United States Food and Drug Administration for the postprandial glucose control of type II diabetes mellitus. Pharmacology; Pharmacokinetics; Clinical trials; Adverse effects;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics